We partner with highly-experienced management teams to seek to build best-of-breed businessesview all
Produces the Impella product line, the world's smallest and minimally invasive micro blood pump
Pan-Latin American specialty pharmaceutical company focused on oncology and critical care drugs
Orthobiologics company focused on bone growth stimulation and joint pain therapies
Trans-Atlantic specialty pharmaceutical company focused on oncology and critical care
"The EW team is extremely knowledgeable, and their ability to identify great innovations and market opportunities, and help move those innovations forward by sharing expertise and assisting in business plan execution is remarkable. AxoGen is proud to have Essex as a partner in our continued growth."
"I have been on the Board of Directors of three EW-backed companies: as Chairman, as Executive Chairman, and as the only US-based Director. EW played a key role in building these three rapidly growing companies. The EW team are true partners with the management teams they back. I look forward to the fourth deal!"
"I am so pleased with our working relationship and the experience, guidance and support that EW provides to EyePoint Pharmaceuticals. The quality of their input, at both the Board level and the management level, has been superb and we have forged a true partnership."
"We are thrilled to partner with EW. With their understanding of the medical device space and how companies should operate, EW has added value from ‘Day 1’. We were very impressed with the careful diligence conducted by the EW team, and we look forward to a great future together!"
Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.